COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

• Status: Active, not recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Frank C Sciurba
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Apixaban; Aspirin

Criteria

Inclusion:

• COVID-19+ in past 14 days

• Platelets > 100,000

• eGFR > 30ml/min

Exclusion:

• Hospitalized

• Contradiction/ other indication for anti-coagulation

• Pregnancy

• Active cancer